Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 6/20 | 0.52 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALPL | P05186 | 1/20 | 0.49 |
| ▸ | ALPI | P09923 | 1/20 | 0.49 |
| ▸ | ALPG | P10696 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4784023 | 0.85 | RAB9A (0.66) | POLBKMT2AMEN1NPC1RAB9A | |
| SCHEMBL3456922 | 0.81 | MEN1 (0.61) | HSD11B1POLBKMT2AMEN1 | |
| SCHEMBL1420778 | 0.78 | ALDH1A1 (0.55) | EPHX2HSD11B1KMT2ARAB9A | |
| SCHEMBL19808478 | 0.78 | EPHX2 (0.66) | EPHX2HSD11B1KMT2A | |
| SCHEMBL19134233 | 0.76 | LMNA (0.72) | POLBKMT2AMEN1RAB9AHPGD | |
| SCHEMBL14438183 | 0.74 | SMN1; SMN2 (0.60) | POLBKMT2AMEN1ALPLALPI | |
| SCHEMBL14112024 | 0.74 | KMT2A (0.77) | POLBKMT2AMEN1HPGD | |
| SCHEMBL2125504 | 0.73 | ALDH1A1 (0.64) | EPHX2KMT2AMEN1NPC1RAB9A | |
| SCHEMBL11353062 | 0.73 | HSD11B1 (0.55) | EPHX2HSD11B1THRB | |
| SCHEMBL12020366 | 0.73 | HSD11B1 (0.47) | EPHX2HSD11B1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101300005-B | N-2 adamantyl-2-phenoxy-acetamide derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors | JANSSEN PHARMACEUTICA NV | 2013-05-01 | — | — | CN | disclosed |
| US-8344181-B2 | Obesity, type 2 diabetes, hyperlipidemia, hypertension, arteriosclerosis, coronary heart diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-01-01 | — | — | US | disclosed |
| EP-2150109-B1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HIGH POINT PHARMACEUTICALS LLC (US) | 2012-09-19 | — | — | EP | disclosed |
| EP-1796657-B1 | N-2 ADAMANTANYL-2-PHENOXY-ACETAMIDE DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-12-23 | — | — | EP | disclosed |
| CN-101300005-A | N-2 adamantyl-2-phenoxy-acetamide derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2008-11-05 | — | — | CN | disclosed |
| US-20080064693-A1 | N-2 Adamantanyl-2-Phenoxy-Acetamide Derivatives as 11-Beta Hydroxysteroid Dehydrogenase Inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-13 | — | — | US | disclosed |
| WO-2006024627-A9 | N-2 ADAMANTANYL-2-PHENOXY-ACETAMIDE DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2008-02-14 | — | — | WO | disclosed |
| EP-1796657-A2 | N-2 ADAMANTANYL-2-PHENOXY-ACETAMIDE DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006024627-A2 | N-2 ADAMANTANYL-2-PHENOXY-ACETAMIDE DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064693-A1 | N-2 Adamantanyl-2-Phenoxy-Acetamide Derivatives as 11-Beta Hydroxysteroid Dehydrogenase Inhibitors | HSD3B1, HSD3B2, HSD11B1 | EPHX2 845/4885HSD11B1 3/4885POLB 2115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.